Corindus
This article was originally published in Start Up
Executive Summary
Now that percutaneous coronary inverventions (PCIs) outnumber coronary bypass surgeries by nearly four to one, interventional cardiologists are spending significantly more time in the cath lab. Because PCIs are performed using radiological guidance, physicians must wear leaded garments to protect them from radiation exposure during lengthy procedures. The weight of these garments can lead to orthopedic back and joint problems over time. Corindus is addressing the occupational hazards that have accompanied PCI's growth with a remote control catheterization system that enables cardiologists to advance and manipulate interventional devices inside patients' arteries from a safe distance.
You may also be interested in...
Israel, Fertile Land for Device Company Creation
A surprisingly large number of medical device start-ups emerge from Israel, and at the recent In3 (Investment in Innovation) conference sponsored by the Medtech Insight division of Windhover Information Inc. in Brussels, Belgium in late September, a distinguished panel of venture capitalists made sense of the country's unique climate for device innovation. The speakers also had some lessons to offer to fledgling European device companies as well. Taking part in the panel were Avi Molcho, MD, Managing Director, Life Sciences, for Giza Venture Capital, one of Israel's largest venture firms, Zeev Zehavi, VP of Johnson & Johnson Development Corp., responsible for J&J's corporate investments in Europe and Israel, and Yuval Binur, PhD, Chairman of the board of device company creator Accelerated Technologies.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.